Greenland Mines Ltd stock is traded at $3.42, with a volume of 314,943. It is down -2.29% in the last 24 hours and down -43.00% over the past month. Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Previous Close:
$3.50
Open:
$3.50
24h Volume:
314,943
Relative Volume:
0.62
Market Cap:
$46.81M
Revenue:
-
Net Income/Loss:
-$22.17M
P/E Ratio:
-
EPS:
-$0.3354
Net Cash Flow:
-$9.97M
1W Performance:
-14.50%
1M Performance:
-43.00%
6M Performance:
-82.25%
1Y Performance:
0.00%
1-Day Range:
$3.37$3.58
1-Week Range:
$3.37$4.11
52-Week Range:
$2.82$27.48
Greenland Mines Ltd Stock (GRML) Company Profile
Name
Greenland Mines LtdSector
Basic MaterialsIndustry
Other Precious Metals & MiningPhone
(833) 931-6330Address
13576 WALNUT STREET, SUITE A, OMAHA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS